Animal studies have demonstrated the critical roles of the patatin-like protein family plays in cellular growth, lipid homeostasis, and second messenger signaling the nervous system. Of the nine known calcium-independent phospholipase A2g, only PNPLA2, PNLPA6, PNPLA9 and most recently a single patient with PNPLA8 are associated with mitochondrial-related neurodegeneration. Using whole exome sequencing, we report two unrelated individuals with variable but similar clinical features of microcephaly, severe global developmental delay, spasticity, lactic acidosis, and progressive cerebellar atrophy with biallelic loss-of-function variants in PNPLA8. We report two additional unrelated individuals with microcephaly, spasticity, lactic acidosis and cerebellum, and brainstem volume loss.
| I N TR ODU C TI ON
Phospholipases A2 are essential for maintenance of normal mitochondrial function and defects can lead to decreased mitochondrial respiration (Kienesberger, Oberer, Lass, & Zechner, 2009 ). The Ca 21 -independent phospholipases A2 (iPLA 2 s) are part of a diverse family of PLA 2 s that hydrolyze membrane phospholipids and do not require calcium for either translocation or activity. They are also designated as group VI iPLA 2 s. The iPLA 2 s are included in the patatin-like protein family due to their shared homology with patatin, a lipid hydrolase and are also referred to as patatin-like phospholipase domain containing proteins (PNPLAs). Currently, nine PNPLAs (PNPLA1-9) are known in humans (Kienesberger et al., 2009) . Recently, biallelic loss-of-function variants in PNPLA8 have been reported in a child with progressive muscle weakness, hypotonia, seizures, poor weight gain, and lactic acidosis (Saunders et al., 2015) .
We report two additional unrelated individuals with microcephaly, spasticity, lactic acidosis and cerebellum, and brainstem volume loss.
Our report validates the progressive neurodegenerative phenotype associated with loss-of-function variants in PNPLA8.
| M ET HOD S
We evaluated two families from two medical centers, with institutional ethics committee approval at both centers. Informed consent was obtained for the use of clinical and research findings for publication.
| Patient 1
A female child was evaluated on the sixth postnatal day in the neonatal intensive care unit for congenital microcephaly and seizures. She was the second born child to a consanguineous couple with a 2-year-old healthy female sibling (Figure 1a ). The prenatal period was unremarkable. Parents mentioned that the third trimester ultrasound suggested microcephaly, but documents of head size were unavailable for review.
The infant was born full term via normal vaginal delivery. Weight was 2,410 g (-2 SD), length 48 cm (-1 SD), and head circumference 29 cm *These authors have contributed equally to the manuscript.
(-4 SD) at birth. On the second day of life, she had clonic movements in all four limbs and excessive cry. She was treated with phenobarbital and phenytoin for seizure control.
On exam, microcephaly and overriding cranial sutures were noted.
She had multifocal clonic seizures and spasticity of all four limbs. Brain magnetic resonance imaging (MRI) showed microcephaly with simplified gyral pattern, hypoplasia of corpus callosum, prominent cisterna magna with hypoplastic cerebellum, brainstem atrophy (Figure 2a-c) . Magnetic resonance spectroscopy (MRS) showed an elevated lipid-lactate peak.
TORCH testing (immunoblotting for toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus 1 and 2) and bacterial culture for blood was negative. Hematology, serum sodium, potassium, calcium, magnesium, C-reactive protein, renal functions tests were normal. Phenotype data can be accessed at www.phenomecentral.org (ID: P0004651).
| Patient 2
This patient presented at 2-years of age. She was born to nonconsanguineous parents. By history, she had normal development until about 13 months of age. She was able to independently sit, stand, cruise, and babble. However, she then regressed concomitantly with several episodes of epilepsy partialis continua and difficult to control focal seizures. 
| R E SU LTS
Clinical and molecular findings in cases with pathogenic variation in PNPLA8 are summarized in Table 1 
| D ISC USSION
Biallelic loss-of-function variants in PNPLA8 were found in two unrelated individuals. The phenotypes of the probands were variable but The gene, PNPLA8 is located at 7q31 and encodes a protein containing 782 amino acids. This enzyme is known to increase prostaglandin E2 production via cyclooxygenase (COX)-1 and -2, which contributes to cell growth and tumorigenesis (Moon et al., 2012) . It has protective effects against oxidant and cytokine-induced cell death. The PNPLA8 (Group VIB phospholipase or iPLA2g) protein has been localized to the inner mitochondrial membrane and is involved in regulation of oxidative stress. PNPLA8 is specific to sn-1 and sn-2 phospholipases with multiple transcription start sites and multiple methods of proteolytic processing (Liu et al., 2017; Tanaka, Takeya, & Sumimoto, 2000; Tang et al., 1997) . Pnpla8 null mice show increased levels of reactive oxygen species resulting in liver mitochondrial swelling, mitochondrial permeability transition pore opening, and cytochrome c release from mitochondria, which trigger the intrinsic apoptotic pathway. Histological findings in Patient 2 of abnormal mitochondria with concentric lamellar membranes and inclusions were in concordance with the observations in the null mice and the patient reported by Saunders et al. (2015) . The null mice also show growth retardation, impaired learning, decreased exercise endurance, enhanced insulin sensitivity, a thin body habitus, cold intolerance, and increased mortality. They exhibit a mitochondrial neurodegenerative disorder characterized by degenerating mitochondria, autophagy, and cognitive decline (Mancuso et al., 2007 (Mancuso et al., , 2009 . A similar phenotype of progressive neurodegeneration is evident in the affected individuals with this condition as well.
The variants observed in PNPLA8, including the ones in our study are loss-of-function pathogenic variants, which introduce a premature stop codon (Figure 1e ). These variants are very likely to result in a trun- 
